Mood and brain
Published human studies in mood, cognition and neurological conditions.
This page lists published studies. It reports what the authors did and found, with the limits of each study. It is not advice.
91 studies listed, newest first.
- Targeting PTSD with ultramicronized palmitoylethanolamide: Results from a randomized trial integrating pharmacotherapy and cognitive behavioral therapyRandomised controlled trialHumans
- Phase 2 study of palmitoylethanolamide combined with luteoline in frontotemporal dementia patientsRandomised controlled trialHumansWith luteolin
- Effects of palmitoylethanolamide in clinical high-risk for psychosis: A nonrandomized open-label trialOpen-label, no control groupHumans
- Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populationsReviewHumans
- The effects of formulated palmitoylethanolamide supplementation on indicators of stress and heart rate variability in female university students: a randomised cross-over trialRandomised controlled trialHumans
- Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune ModulationReviewHumansOther animals
- Therapeutic potential of clinically proven natural products in the management of dementiaReviewHumans
- EXPRESSION OF CONCERN: Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of AutismReviewOther animalsHumansWith luteolin
- Endocannabinoids, endocannabinoid-like compounds and cortisone in head hair of health care workers as markers of stress and resilience during the early COVID-19 pandemicObservational studyHumans
- PEALut in the Dietary Management of Patients with Acute Ischemic Stroke: A Prospective Randomized Controlled Clinical TrialControlled trialHumansWith luteolin (co-ultramicronised palmitoylethanolamide and luteolin, PEALut)
- Assessing the biobehavioral effects of ultramicronized-palmitoylethanolamide monotherapy in autistic adults with different severity levels: a report of two casesCase seriesHumans
- The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for PsychosisOpen-label, no control groupHumans
- Dysfunction in endocannabinoids, palmitoylethanolamide, and degradation of tryptophan into kynurenine in individuals with depressive symptomsObservational studyHumans
- Cannabinoids and Sleep: Exploring Biological Mechanisms and Therapeutic PotentialsReviewHumans
- Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults: A Randomised Cross-Over TrialRandomised controlled trialHumans
- Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivorsObservational studyHumans
- Emerging drugs for the treatment of irritability associated with autism spectrum disorderReviewHumans
- Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidenceReviewHumans
- To Go Where Nature Leads: Focus on Palmitoylethanolamide and Related ALIAmides as Innovative Approach to Neuroinflammatory and Pain-Related Disease States in Honor of Doctor Francesco Della ValleReviewHumans
- Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?Observational studyHumansWith luteolin (co-ultramicronised PEA-LUT), with olfactory training
- Parosmia COVID-19 Related Treated by a Combination of Olfactory Training and Ultramicronized PEA-LUT: A Prospective Randomized Controlled TrialRandomised controlled trialHumansWith luteolin (co-ultramicronised PEA-LUT), with olfactory training
- Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder PatientsObservational studyHumans
- Longitudinal course of endocannabinoids and N-acylethanolamines in hair of mothers and their children in the first year postpartum: investigating the relevance of maternal childhood maltreatment experiencesObservational studyHumans
- Plasma endocannabinoids in cocaine dependence and their relation to cerebral metabotropic glutamate receptor 5 densityObservational studyHumans
- Inhibiting immunoregulatory amidase NAAA blocks ZIKV maturation in Human Neural Stem CellsLaboratory studyHumans
- Sex differences in endocannabinoid tone in a pilot study of cannabis use disorder and acute cannabis abstinenceObservational studyHumans
- Hair endocannabinoids predict physiological fear conditioning and salivary endocannabinoids predict subjective stress reactivity in humansObservational studyHumans
- Role of PPAR-Allopregnanolone Signaling in Behavioral and Inflammatory Gut-Brain Axis CommunicationsReviewHumansOther animals
- What Is the Role of Palmitoylethanolamide Co-Ultramicronized with Luteolin on the Symptomatology Reported by Patients Suffering from Long COVID? A Retrospective Analysis Performed by a Group of General Practitioners in a Real-Life SettingObservational studyHumansWith luteolin
- Could serum endocannabinoid and N-acylethanolamine levels be important in bipolar disorder?Observational studyHumans
- Neuro-Gastro-Cannabinology: A Novel Paradigm for Regulating Mood and Digestive HealthReviewHumans
- Endocannabinoid and perceived stress: Association analysis of endocannabinoid levels in hair versus levels in plasma and urineObservational studyHumans
- Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndromeRandomised controlled trialHumansWith luteolin
- Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trialRandomised controlled trialHumans
- Review of Alzheimer's disease drugs and their relationship with neuron-glia interactionReviewHumansOther animals
- Synaptic Effects of Palmitoylethanolamide in Neurodegenerative DisordersReviewHumansOther animalsWith luteolin
- Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidenceMeta-analysisHumansOther animals
- Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal StudyOpen-label, no control groupHumansWith luteolin
- Investigational drugs for the treatment of olfactory dysfunctionReviewHumans
- MED1/BDNF/TrkB pathway is involved in thalamic hemorrhage-induced pain and depression by regulating microgliaLaboratory studyOther animalsHumansWith luteolin (co-ultramicronised PEA plus luteolin, PEALut)
- Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to HumansReviewHumansOther animals
- Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonismLaboratory studyHumansOther animalsWith NAAA gene deletion or NAAA inhibitors, which raise the body's own palmitoylethanolamide; PEA itself was not given
- The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up StudyObservational studyHumans
- Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical ApplicationsReviewHumans
- Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trialRandomised controlled trialHumans
- Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarateObservational studyHumans
- Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional ViewpointReviewDogsCatsHumans
- Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic ImplicationsReviewHumansOther animals
- Alterations of Stress-Related Glucocorticoids and Endocannabinoids in Hair of Chronic Cocaine UsersObservational studyHumans
- Hair-based biomarkers in women with major depressive disorder: Glucocorticoids, endocannabinoids, N-acylethanolamines, and testosteroneObservational studyHumans
- A Phase-2 Pilot Study of a Therapeutic Combination of Delta-9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette's SyndromeOpen-label, no control groupHumansWith delta-9-tetrahydrocannabinol (THC)
- Palmitoylethanolamide/Luteolin as Adjuvant Therapy to Improve an Unusual Case of Camptocormia in a Patient with Parkinson's Disease: A Case ReportCase seriesHumansWith luteolin (co-ultramicronised with palmitoylethanolamide, um-PEALut)
- Co-Ultra PEALut Enhances Endogenous Repair Response Following Moderate Traumatic Brain InjuryLaboratory studyHumansOther animalsWith luteolin (co-ultramicronised PEA plus luteolin, Glialia)
- Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal EvidenceReviewHumansOther animals
- Endocannabinoid markers in autism spectrum disorder: A scoping review of human studiesReviewHumans
- The immune system and autism spectrum disorder: association and therapeutic challengesReviewHumans
- Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohortObservational studyHumans
- Conjugated Linoleic Acid and Brain Metabolism: A Possible Anti-Neuroinflammatory Role Mediated by PPARα ActivationReviewHumansOther animals
- NAPE-specific phospholipase D regulates LRRK2 association with neuronal membranesLaboratory studyHumansOther animals
- Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammationReviewHumans
- The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept studyRandomised controlled trialHumansWith JNJ-42165279 (a FAAH inhibitor that raises endogenous PEA, anandamide and OEA, tested alone)
- Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the EvidenceReviewHumans
- Hair endocannabinoid concentrations in individuals with acute and weight-recovered anorexia nervosaObservational studyHumans
- Sepsis-associated encephalopathy and septic encephalitis: an updateReviewHumans
- Alternative Targets to Fight Alzheimer's Disease: Focus on AstrocytesReviewHumansOther animals
- Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoidsObservational studyHumans
- Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions, High Frequency Oscillations, and GABAergic Transmission in Patients with Frontotemporal DementiaOpen-label, no control groupHumansWith luteolin (PEA-LUT)
- Associating Emergency Medical Services personnel's workload, trauma exposure, and health with the cortisol, endocannabinoid, and N-acylethanolamine concentrations in their hairObservational studyHumans
- Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of NeuroinflammationLaboratory studyHumansOther animals
- An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory EventsReviewHumansOther animalsWith luteolin
- Endocannabinoid concentrations in hair and mental health of unaccompanied refugee minorsObservational studyHumans
- Management of Traumatic Brain Injury: From Present to FutureReviewHumansOther animals
- ENDOCANNABINOIDS RECEPTORS MEDIATED CENTRAL AND PERIPHERAL EFFECTS (REVIEW)ReviewHumansOther animals
- Food supplements based on palmitoylethanolamide plus hydroxytyrosol from olive tree or Bacopa monnieri extracts for neurological diseasesReviewHumansOther animalsWith hydroxytyrosol (olive extract) and Bacopa monnieri extract, discussed as supplement partners
- Dietary interventions for multiple sclerosis-related outcomesMeta-analysisHumans
- Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries. A Systematic ReviewReviewHumans
- Effects of the glial modulator palmitoylethanolamide on chronic pain intensity and brain functionOpen-label, no control groupHumans
- Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer's DiseaseReviewHumansOther animalsWith luteolin (in the single case study cited)
- Role of palmitoylethanolamide (PEA) in depression: Translational evidenceReviewHumansOther animals
- Co-ultraPEALut: Role in Preclinical and Clinical Delirium ManifestationsControlled trialHumansOther animalsWith luteolin
- Serum Endocannabinoid and Mood Changes after Exercise in Major Depressive DisorderControlled trialHumans
- Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of TreatmentOpen-label, no control groupHumans
- Oligodendrocyte precursor cells as a therapeutic target for demyelinating diseasesReviewHumansOther animals
- Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trialRandomised controlled trialHumans
- Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trialRandomised controlled trialHumans
- Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson's DiseaseObservational studyHumans
- Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidenceLaboratory studyHumansOther animals
- Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to ManObservational studyHumansOther animalsWith luteolin
- Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple SclerosisRandomised controlled trialHumans
- Acetylcholine receptors from human muscle as pharmacological targets for ALS therapyObservational studyHumans
- Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two CasesCase seriesHumans